Search results
15 wrz 2022 · A commonly accepted paradigm (based on Virchow’s triad of thrombogenesis) posits the pathogenesis of LV thrombus as occurring as a result of the interplay of 3 factors: (1) stasis attributable to reduced ventricular function, (2) endocardial injury, and (3) inflammation/hypercoagulability (Figure 1).
- View EPUB
(r·=™Z¢ÔþÛôn =Yj > h~}¤ÄŽ@ ]|Ÿög š×/|ë@¾l÷ †u¢ÚsÅCÈù?\yÓ©b...
- Linda S. Williams
These results were statistically significant compared with...
- PDF/Epub
PK u!3Yoa«, mimetypeapplication/epub+zipPK u!3Y...
- Trial
Background—The Randomized Evaluation of Long-term...
- Results From the GEIST
Left ventricular (LV) thrombus formation is a well‐known...
- Intraventricular Thrombus Formation and Embolism in Takotsubo Syndrome
Objective: Takotsubo syndrome (TTS) is characterized by...
- Stroke
National Center. 7272 Greenville Ave.Dallas, TX 75231....
- Peripartum Cardiomyopathy
Peripartum cardiomyopathy is a potentially life-threatening...
- View EPUB
Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies. AHA Guideline and Statements Hub content for Management of Patients at Risk for and with Left Ventricular Thrombus.
23 wrz 2022 · If OAC is initiated, a treatment duration might be 1–3 months, depending on bleeding risk. On the basis of reasonable data and evidence, post-MI patients with LV thrombus should be treated with OAC, typically for a duration of 3 months.
14 wrz 2022 · We suggest that, on the basis of limited data, patients with NICM with LV thrombus should be treated with OAC for at least 3–6 mo, with dis-continuation if LVEF improves to >35% (assuming resolution of the LV thrombus) or if major bleeding occurs.
Left ventricular (LV) thrombus is a feared complication of LV dysfunction associated with high rates of systemic embolism, morbidity, and mortality. Traditionally, LV thrombus has been associated with acute myocardial infarction (MI).
1 mar 2021 · Abstract. Left ventricular thrombus (LVT) is a serious complication of acute myocardial infarction (MI) and also non-ischemic cardiomyopathies. We performed a narrative literature review, manual-search of reference lists of included articles and relevant reviews.
Management of LV thrombus (LVT) is challenging and crucial to prevent the potential development of thromboembolic complications such as stroke. Anticoagulation with warfarin is recommended for the prevention of thromboembolic events, but novel oral anticoagulants (NOAC) have been used in clinical practice without supporting evidence.
